Evidence map›Paper›PMID 28968180›Full record

ArticleVirulence2018

Immunomodulatory properties of Brucella melitensis lipopolysaccharide determinants on mouse dendritic cells in vitro and in vivo.

Yun Zhao, Sean Hanniffy, Vilma Arce-Gorvel, Raquel Conde-Alvarez, SangKon Oh, Ignacio Moriyón, Sylvie Mémet, Jean-Pierre Gorvel

Open access · goldAbstract read
In one paragraph

Article in Virulence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Enhanced immunogenicity of theFrontiers in immunology · 2026
    Article
  3. Article
  4. Article
  5. Frontiers in cellular and infection microbiology · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. The Mechanism of Facultative Intracellular Parasitism ofInternational journal of molecular sciences · 2021
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. WadD, a NewFrontiers in microbiology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Yun Zhaoa Centre d'Immunologie de Marseille-Luminy, CIML, Aix Marseille Univ, CNRS, INSERM , Marseille , France.
Sean Hanniffya Centre d'Immunologie de Marseille-Luminy, CIML, Aix Marseille Univ, CNRS, INSERM , Marseille , France.
Vilma Arce-Gorvela Centre d'Immunologie de Marseille-Luminy, CIML, Aix Marseille Univ, CNRS, INSERM , Marseille , France.
Raquel Conde-Alvarezb Departamento de Microbiología y Parasitología , Instituto de Salud Tropical, Instituto de Investigación Sanitaria de Navarra, Universidad de Navarra , c/Irunlarrea 1, Pamplona , Spain.
SangKon Ohc Baylor Institute for Immunology Research , 3434 Live Oak St., Dallas , TX , U.S.A.
Ignacio Moriyónb Departamento de Microbiología y Parasitología , Instituto de Salud Tropical, Instituto de Investigación Sanitaria de Navarra, Universidad de Navarra , c/Irunlarrea 1, Pamplona , Spain.
Sylvie Mémeta Centre d'Immunologie de Marseille-Luminy, CIML, Aix Marseille Univ, CNRS, INSERM , Marseille , France.
Jean-Pierre Gorvela Centre d'Immunologie de Marseille-Luminy, CIML, Aix Marseille Univ, CNRS, INSERM , Marseille , France.
Centre d’Immunologie de Marseille-Luminy · FRNavarre Institute of Health Research · ESBaylor University · USCentre National de la Recherche Scientifique · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The lipopolysaccharide (LPS) is a major virulence factor of Brucella, a facultative intracellular pathogenic Gram-negative bacterium. Brucella LPS exhibits a low toxicity and its atypical structure was postulated to delay the host immune response, favouring the establishment of chronic disease. Here we carried out an in-depth in vitro and in vivo characterisation of the immunomodulatory effects of Brucella LPS on different dendritic cell (DC) subpopulations. By using LPSs from bacteria that share some of Brucella LPS structural features, we demonstrated that the core component of B. melitensis wild-type (Bm-wt) LPS accounts for the low activation potential of Brucella LPS in mouse GM-CSF-derived (GM-) DCs. Contrary to the accepted dogma considering Brucella LPS a poor TLR4 agonist and DC activator, Bm-wt LPS selectively induced expression of surface activation markers and cytokine secretion from Flt3-Ligand-derived (FL-) DCs in a TLR4-dependent manner. It also primed in vitro T cell proliferation by FL-DCs. In contrast, modified LPS with a defective core purified from Brucella carrying a mutated wadC gene (Bm-wadC), efficiently potentiated mouse and human DC activation and T cell proliferation in vitro. In vivo, Bm-wt LPS promoted scant activation of splenic DC subsets and limited recruitment of monocyte- DC like cells in the spleen, conversely to Bm-wadC LPS. Bm-wadC live bacteria drove high cytokine secretion levels in sera of infected mice. Altogether, these results illustrate the immunomodulatory properties of Brucella LPS and the enhanced DC activation ability of the wadC mutation with potential for vaccine development targeting Brucella core LPS structure.

Indexed as

AnimalsBrucella melitensisCell ProliferationCells, CulturedCytokinesDendritic CellsHumansLipopolysaccharidesMiceSpleenT-LymphocytesToll-Like Receptor 4CytokinesLipopolysaccharidesTlr4 protein, mouseToll-Like Receptor 4Brucelladendritic cellintracellular bacterialipopolysaccharideT cell proliferationtoll-like receptorvaccine

Identifiers

PMID28968180
PMCPMC5955181
OpenAlexW2761361241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.